The Top 5 Biosimilar Articles for the Week of October 5

Here are the top 5 biosimilar articles for the week of October 5, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of October 5, 2020.

Number 5: The European Medicines Agency has initiated review of a proposed ranibizumab biosimilar (SB11) from Samsung Bioepis.

Number 4:Of the 54 biosimilars approved by the European Medicines Agency (EMA) as of August 2019, fewer than half are available in Slovakia, but if the remaining 30 biosimilars were available, the nation’s health fund could save between €35 million and €50 million per year, according to a new study.

Number 3: A group of researchers from the biosimilar industry and academia have recommended in a review that the FDA widen the scope of acceptable studies for determining interchangeable status for biosimilars.

Number 2: According to a report from the IQVIA Institute for Human Data Science, biosimilars could generate sales of $80 billion over the next 5 years and potential biosimilar-generated health care savings could reach more than $100 billion during that same period.

Number 1: Accord brought 2 biosimilars referencing blockbuster oncology products to the United Kingdom and amended its agreement with Shanghai Henlius Biotech.

To read all of these articles and more, visit